Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: A prospective, non-randomized pilot study

European Journal of Neurology

Volumn 20, Issue 6, 2013, Pages 986-990

  Portaccio, E ^a   Stromillo, M L ^b   Goretti, B ^a   Hakiki, B ^a   Giorgio, A ^b   Rossi, F ^b   De Leucio, A ^b   De Stefano, N ^b   Amato, M P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Atrophy; Cognitive impairment; Interferon beta; magnetic resonance; Multiple sclerosis; Natalizumab

Indexed keywords

BETA INTERFERON; GLATIRAMER; NATALIZUMAB;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; MALE; MEASUREMENT ERROR; MENTAL DETERIORATION; MENTAL PERFORMANCE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; WHITE MATTER;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATROPHY; BRAIN; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 84877655133     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03882.x     Document Type: Article

References (24)

1. Amato MP, Zipoli V, Portaccio E. Cognitive changes in multiple sclerosis. Expert Rev Neurother 2008; 8: 1585-1596.
2. Zipoli V, Goretti B, Hakiki B, et al. Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult Scler 2010; 16: 62-67.
3. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001; 58: 1602-1606.
4. Amato MP, Portaccio E, Goretti B, et al. Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Mult Scler 2010; 16: 1474-1482.
5. Filippi M, Rocca MA, Benedict RH, et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 2010; 75: 2121-2128.
6. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
8. Rao S. A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. Milwaukee, WI: Medical College of Wisconsin, 1990.
9. Amato MP, Portaccio E, Goretti B, et al. The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler 2006; 12: 787-793.
10. Amato MP, Hakiki B, Goretti B, et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology 2012; 78: 309-314.
11. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479-489.
12. Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 2012; 33: 2062-2071.
13. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157-1162.
14. Portaccio E, Goretti B, Zipoli V, et al. Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery. Mult Scler 2010; 16: 611-617.
15. Vosoughi R, Freedman MS. Therapy of MS. Clin Neurol Neurosurg 2010; 112: 365-385.
16. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48: 885-892.
17. Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996; 47: 1463-1468.
18. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987-997.
19. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 2002; 47: 11-14.
20. Patti F, Amato MP, Bastianello S, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 2010; 16: 68-77.
21. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
22. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
23. Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci 2011; 32: 83-88.
24. Lang C, Reiss C, Maurer M. Natalizumab may improve cognition and mood in multiple sclerosis. Eur Neurol 2012; 67: 162-166.